Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.

Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child Adolesc Health. 2018 01; 2(1):25-34.

View in: PubMed

subject areas

Anti-Inflammatory Agents
Antineoplastic Combined Chemotherapy Protocols
Ataxia
Child
Child, Preschool
Disease-Free Survival
Female
Humans
Immunoglobulins, Intravenous
Infant
Male
Neuroblastoma
Neurologic Examination
Opsoclonus-Myoclonus Syndrome
Prednisone
Severity of Illness Index

authors with profiles

Susan L. Cohn